Patents Examined by Michael G. Hartley
  • Compositions and methods for assessing gut function
    Patent number: 11077211
    Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: August 3, 2021
    Assignee: MediBeacon Inc.
    Inventors: Richard B Dorshow, Steven J. Hanley, Phillip I. Tarr
  • Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application
    Patent number: 11071794
    Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: July 27, 2021
    Assignee: Five Eleven Pharma Inc.
    Inventors: Zehui Wu, Zhihao Zha, Futao Liu, Karl Ploessl, Seok Rye Choi, Hank F. Kung
  • Targeted gas-filled microvesicles formulation
    Patent number: 11071792
    Abstract: Suspension of gas-filled microvesicles comprising a targeting ligand for binding to KDR or VEGF/KDR complex. The suspension is obtained by reconstituting a freeze-dried residue with a carbohydrate-containing solution in the presence of a physiologically acceptable gas and is stabilized by the presence of histidine.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: July 27, 2021
    Assignee: Braceo Suisse SA
    Inventors: Philippe Bussat, Anne Lassus
  • Probes for imaging huntingtin protein
    Patent number: 11071793
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: July 27, 2021
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Thomas Martin Krülle, Daniel Clark-Frew, Sarah Hayes
  • Gel formulations for local drug release
    Patent number: 11065201
    Abstract: The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: July 20, 2021
    Assignee: TECHNICAL UNIVERSITY OF DENMARK
    Inventors: Thomas Lars Andresen, Linda Maria Bruun, Trine Bjørnbo Larsen, Rasmus Irming Jølck, Anders Elias Hansen
  • 18F labeled BODIPY dye and its derivatives for PET imaging of heart perfusion and others
    Patent number: 11065349
    Abstract: This invention provides a class of dual mode imaging tracer capable of acting both as a fluorescent imaging tracer and a positron emission tomography imaging tracer. Tracers in accordance with this invention generally have a fluorescent core with a boron-fluoride element embedded therein. Exemplary embodiments of the tracer include 18F-labeled BODIPY compounds and derivative thereof. Also provided are tracer kits containing a sterile formulation of a BODIPY dye either in a radio-labeled or pre-labeled state, and methods for imaging heart perfusion using the 18F-labeled dual mode tracers.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 20, 2021
    Inventors: Peter S. Conti, Zibo Li, Shuanglong Liu, Dan Li
  • Apparatus and methods for making recombinant protein-stabilized monodisperse microbubbles
    Patent number: 11065348
    Abstract: A microfluidic device for generating microbubbles includes a substrate and a microfluidic channel embedded in the substrate. The microfluidic channel includes a plurality of fluid inlets, at least one bubble formation outlet having a nozzle with an adjustable diameter, and a flow focusing junction in fluid communication with the plurality of fluid inlets and the bubble formation outlet. A method for mass producing monodisperse microbubbles with a microfluidic device includes supplying a flow of dispersed phase fluid into a first fluid inlet of a microfluidic channel, supplying a flow of continuous phase fluid into a second fluid inlet of the microfluidic channel, and adjusting a diameter of a nozzle to obtain a plurality of monodisperse microbubbles having a specified diameter.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: July 20, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daeyeon Lee, Francesco Angile, Kevin Vargo, Daniel A. Hammer, Chandra M. Sehgal
  • Probes for imaging huntingtin protein
    Patent number: 11059836
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 13, 2021
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Samuel Coe, Peter David Johnson, Michael Edward Prime, Christopher John Brown, Sébastien René Gabriel Galan, Paul Richard Giles, Jonathan Bard, Elise Luciennen Paulette Gadouleau, Thomas Martin Krülle, Daniel Clark-Frew, John Wityak, Alex Kiselyov, Sarah Hayes
  • CXCR7 antagonists
    Patent number: 11059825
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: July 13, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Liposomal gadolinium (GD) contrast agent “NMRX” for T1-MRI
    Patent number: 11052162
    Abstract: The present invention is directed towards new chemical entities based on a lipid-paramagnetic metal ion chelate. The lipid portion of the compound intercalates into the membrane of a liposome. The compounds of the invention find particular use as paramagnetic contrast media for magnetic resonance imaging. It has been surprisingly discovered that the liposomal contrast media do not substantially cross the placental barrier into the vasculature of the fetus(es) when administered to a pregnant subject. These novel compounds are useful in the diagnosis of disorders and diseases in both gravid and non-gravid subjects. The invention is also directed towards pharmaceutical compositions comprising these compounds and the uses of these compounds.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: July 6, 2021
    Assignee: TEXAS CHILDREN'S HOSPITAL
    Inventors: Ananth Annapragada, Anil Shetty, Ketankumar B Ghaghada, Eric Tanifum
  • Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
    Patent number: 11052157
    Abstract: Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: July 6, 2021
    Assignee: ENGENEIC MOLECULAR DELIVERY PTY LTD.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Compositions and associated methods for radioisotope-binding microparticles
    Patent number: 11052164
    Abstract: The present disclosure relates to polymeric materials that may be labeled with a radioisotope, to processes for producing the labeled polymeric material, and to methods of using the materials in analytical and therapeutic applications. Specifically, the disclosure relates to injectable and implantable microparticles, such as microspheres, which are associated with radioisotopes such that the microparticles are both therapeutic and detectable. The radioisotope-containing microparticles are useful for embolization and other therapeutic medical applications.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: July 6, 2021
    Assignee: Biosphere Medical, Inc.
    Inventors: Philippe Reb, Celine Chaix
  • Reactive fluorogenic compound and nanocomposite for sensing hydrogen sulfide comprising the same
    Patent number: 11045559
    Abstract: The present invention relates to a nanocomposite for detecting hydrogen sulfide; a method for preparing the same; a novel reactive fluorogenic compound to be used in the method; a kit for detecting hydrogen sulfide comprising the nanocomposite; and a method for providing information for the diagnosis of a disease, which causes abnormal secretion of hydrogen sulfide, by using the nanocomposite.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 29, 2021
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Sehoon Kim, Myung Kim, Young Hun Seo, Jungyun Heo, Youngsun Kim
  • Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
    Patent number: 11045564
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 29, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Radiolabelled mGluR2/3 PET ligands
    Patent number: 11045562
    Abstract: The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 29, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: José Ignacio Andrés-Gil, Michiel Luc Maria Van Gool, Guy Maurits R Bormans, Joost Verbeek
  • Method for preparation of highly polarized nuclear spins containing samples and uses thereof for NMR and MRI
    Patent number: 11041928
    Abstract: A method tor the preparation of a highly polarized nuclear spins containing sample of an organic or inorganic material, containing H or OH groups or adsorbed water molecules. Such highly polarized nuclear spins containing samples can be subjected to nuclear magnetic resonance (NMR) measurement and/or can be thawed and immediately administered to an individual undergoing a magnetic resonance imaging (MRI) scan. The method is based on generating unstable radicals on the surface of the sample in the presence of ionized environment followed by cooling the sample to cryogenic temperatures. A device for carrying out a particular step of said method is also discloses.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: June 22, 2021
    Assignees: Technion Research & Development Foundation Limited, Yeda Research and Development Co. Ltd.
    Inventors: Aharon Blank, Itai Katz, Akiva Feintuch
  • Histone acetyltransferase activators and uses thereof
    Patent number: 11034647
    Abstract: The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: June 15, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Yan Feng, Mauro Fa, Ottavio Arancio, Shixian Deng, Donald W. Landry, Yitshak Francis
  • In vivo detection of phospholipase activation
    Patent number: 11034994
    Abstract: The present invention is directed to a phospholipid-based NIR molecular beacon, having a phospholipid moiety; with an NIR fluorophore moiety covalently linked to a phospholipid glycerol backbone and a quencher moiety covalently linked to the phospholipid glycerol backbone. Additionally, provided herein is methods of analyzing a sample for the presence of a phospholipase and methods of identifying the activity of a phospholipase in vivo utilizing phospholipid-based NIR molecular beacon.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: June 15, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Edward J. Delikatny, Anatoliy V. Popov, Gang Zheng, Theresa Mawn
  • Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
    Patent number: 11033642
    Abstract: The invention relates to octadentate ligands of a general formula R1-D-X-D-X-D-X-D-E-R2, wherein D is C(O)N(OH) or N(OH)C(O), pyrimidinone or pyridinone, each X independently of any other X is a saturated or partially unsaturated, substituted or unsubstituted linker comprising 8-11 atoms selected from any of N, C, O; R1 is alkyl, cycloalkyl, arene, or heteroarene, E is a saturated or partially unsaturated, substituted or unsubstituted chain comprising 1-50 atoms and R2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: June 15, 2021
    Assignees: UNIVERSITAT ZURICH, UNIVERSITATSSPITAL BASEL
    Inventors: Malay Patra, Gilles Gasser, Thomas L. Mindt, Andreas Bauman
  • Radiolabelled mGluR2/3 pet ligands
    Patent number: 11033641
    Abstract: The present invention relates to novel, radiolabelled mGluR2/3 ligands, selective 5 versus other mGlu receptors, which are useful for imaging and quantifying the metabotropic glutamate receptors mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or 10 in vivo and to precursors of said compounds.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 15, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: José Ignacio Andrés-Gil, Michiel Luc Maria Van Gool, Guy Maurits R Bormans, Joost Verbeek